Brief: Arya Sciences Acquisition Corp Iv And Amicus Therapeutics, Inc. Mutually Agree To Terminate Business Combination Agreement With Respect To The Acquisition Of Amicus’ Gene Therapy Business Due To Market Conditions
Feb 24 (Reuters) - ARYA Sciences Acquisition Corp IV
ARYD.O :
* ARYA SCIENCES ACQUISITION CORP IV AND AMICUS THERAPEUTICS,
INC.
MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT WITH
RESPECT TO THE ACQUISITION OF AMICUS’ GENE THERAPY BUSINESS DUE
TO MARKET CONDITIONS
* ARYA SCIENCES ACQUISITION IV CORP - STILL HAS OVER A YEAR
REMAINING TO IDENTIFY AND EXECUTE ON A BUSINESS COMBINATION
TRANSACTION
* ARYA SCIENCES ACQUISITION IV CORP - NEITHER PARTY WILL BE
REQUIRED TO PAY OTHER A TERMINATION FEE
Source text for Eikon: ID:nGNX7ydwPR
Further company coverage: ARYD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagio Medical Holdings
See all newsBrief: Adagio Medical To Reduce Workforce By 25 Of 43 Employees Effective Sept 23, 2026 - SEC Filing
Brief: Adagio Medical Announces Strategic Review Process To Maximize Shareholder Value
Adagio Medical Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Adagio Medical Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Adagio Medical Reports Second Quarter 2026 Results